Comment on: "Drug–Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"-Reference-Cited by-同舟云学术

Comment on: "Drug–Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"

Published:2022-06-17 Issue:7 Volume:45 Page:809-811
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Noguchi Yoshihiro^ORCID

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-022-01191-2.pdf

Reference14 articles.

1. Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble JM. Drug-drug interaction of the sodium glucose co-transporter 2 inhibitors with statins and myopathy: a disproportionality analysis using adverse events reporting data. Drug Saf. 2022;45:287–95 https://doi.org/10.1007/s40264-022-01166-3.

2. Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. Acta Diabetol. 2020;57:71–80. https://doi.org/10.1007/s00592-019-01378-7.

3. van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2000;56:733–8. https://doi.org/10.1007/s002280000215.

4. Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64:489–95. https://doi.org/10.1111/j.1365-2125.2007.02900.x.

5. Kuss O, Rathmann W. A missed protective drug-drug interaction of DPP-4 inhibitors and statins on myopathy risk. Acta Diabetol. 2020;57:113–4. https://doi.org/10.1007/s00592-019-01440-4.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use;BMC Pharmacology and Toxicology;2024-02-01

2. Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis;British Journal of Clinical Pharmacology;2023-03-28

3. Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.”;Drug Safety;2022-06-17